The Patent Finder

Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (2022)

Nuvation Bio Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 11,834,458Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
In force
 · High confidence
Nuvation Bio Inc.In forceHigh confidence
Application 18/484,259Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
Abandoned
Abandoned Jun 20, 2025
Nuvation Bio Inc.AbandonedAbandoned Jun 20, 2025
Application 19/228,575Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
Pending
Not granted
Nuvation Bio Inc.PendingNot granted
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Nuvation Bio Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited